Literatura académica sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Antimicrobial PEPTIDES IN VIVO".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Bals, Robert, Daniel J. Weiner, A. David Moscioni, Rupalie L. Meegalla y James M. Wilson. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide". Infection and Immunity 67, n.º 11 (1 de noviembre de 1999): 6084–89. http://dx.doi.org/10.1128/iai.67.11.6084-6089.1999.
Texto completoSchouten, Gina, Felix Paulussen, Oscar Kuipers, Wilbert Bitter, Tom Grossmann y Peter van Ulsen. "Stapling of Peptides Potentiates the Antibiotic Treatment of Acinetobacter baumannii In Vivo". Antibiotics 11, n.º 2 (19 de febrero de 2022): 273. http://dx.doi.org/10.3390/antibiotics11020273.
Texto completoKopeykin, P. M., M. S. Sukhareva, N. V. Lugovkina y O. V. Shamova. "CHEMICAL SYNTHESIS AND ANALYSIS OF ANTIMICROBIAL AND HEMOLYTIC ACTIVITY OF STRUCTURAL ANALOGOUS OF A PEPTIDE PROTEGRIN 1". Medical academic journal 19, n.º 1S (15 de diciembre de 2019): 169–70. http://dx.doi.org/10.17816/maj191s1169-170.
Texto completoHu, Alvin. "Conjugation of Silver Nanoparticles With De Novo–Engineered Cationic Antimicrobial Peptides: Exploratory Proposal". JMIR Research Protocols 10, n.º 12 (8 de diciembre de 2021): e28307. http://dx.doi.org/10.2196/28307.
Texto completoMoser, Christian, Daniel J. Weiner, Elena Lysenko, Robert Bals, Jeffrey N. Weiser y James M. Wilson. "β-Defensin 1 Contributes to Pulmonary Innate Immunity in Mice". Infection and Immunity 70, n.º 6 (junio de 2002): 3068–72. http://dx.doi.org/10.1128/iai.70.6.3068-3072.2002.
Texto completoYeaman, Michael R., Kimberly D. Gank, Arnold S. Bayer y Eric P. Brass. "Synthetic Peptides That Exert Antimicrobial Activities in Whole Blood and Blood-Derived Matrices". Antimicrobial Agents and Chemotherapy 46, n.º 12 (diciembre de 2002): 3883–91. http://dx.doi.org/10.1128/aac.46.12.3883-3891.2002.
Texto completoBhargavi Ram, Thimmiah, Chien Chien Belinda Tang, Siaw Fui Kiew, Sie Yon Lau, Gobi Gobi, Jeevanandam Jaison y Michael K. Danquah. "Nanoformulation of Peptides for Pharmaceutical Applications: In Vitro and In Vivo Perspectives". Applied Sciences 12, n.º 24 (13 de diciembre de 2022): 12777. http://dx.doi.org/10.3390/app122412777.
Texto completoBoullet, Héloise, Fayçal Bentot, Arnaud Hequet, Carine Ganem-Elbaz, Chérine Bechara, Emeline Pacreau, Pierre Launay et al. "Small AntiMicrobial Peptide with In Vivo Activity Against Sepsis". Molecules 24, n.º 9 (1 de mayo de 2019): 1702. http://dx.doi.org/10.3390/molecules24091702.
Texto completoZhang, Lijuan, Jody Parente, Scott M. Harris, Donald E. Woods, Robert E. W. Hancock y Timothy J. Falla. "Antimicrobial Peptide Therapeutics for Cystic Fibrosis". Antimicrobial Agents and Chemotherapy 49, n.º 7 (julio de 2005): 2921–27. http://dx.doi.org/10.1128/aac.49.7.2921-2927.2005.
Texto completoRodrigues, Elaine G., Andrey S. Dobroff, Carlos P. Taborda y Luiz R. Travassos. "Antifungal and antitumor models of bioactive protective peptides". Anais da Academia Brasileira de Ciências 81, n.º 3 (septiembre de 2009): 503–20. http://dx.doi.org/10.1590/s0001-37652009000300015.
Texto completoTesis sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Waldbrook, Matthew George. "In vivo efficacy of novel antibacterial and immunomodulatory peptides". Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/2850.
Texto completoPelillo, Chiara. "Therapeutic potential of BAC7(I-35), a Proline-rich Antimicrobial Peptide: in vitro and in vivo studies and Pegylation strategy to improve its bioavailability". Doctoral thesis, Università degli studi di Trieste, 2011. http://hdl.handle.net/10077/5978.
Texto completoThe antimicrobial peptides (AMPs) are an important component of the innate defense against invading microorganisms, are widespread in nature and may have multiple and diversified mechanisms of bactericidal action. In addition to their direct antimicrobial activity the are also involved in other biological processes. The aim of this project was to investigate the in vivo activity of Bac7(1-35), a bovine proline-rich antimicrobial peptide, having in mind its possible use as a lead compound for the development of novel anti-infective agents. Before moving to animal models of infection, the in vitro stability of the peptide in the presence of murine and human serum or plasma as well as its biodistribution in mouse were investigated. Antibacterial activity assays against Salmonella enterica showed that the presence of murine blood components largely inhibits the antibacterial activity of the peptide. On the contrary, in human serum and plasma Bac7(1-35) maintains its efficacy. This is due to the more rapid degradation by proteases of murine blood. The in vivo biodistribution of Bac7(1-35) was investigated by using a time-domain optical imaging apparatus and a fluorescently-labeled Bac7(1-35) derivative. The compound reaches the kidney and the bladder respectively 1 and 3 hours after i.p. injection. The in vivo and ex vivo analyses performed after 24 h confirm that the compound has been totally excreted. A mouse model of S. typhimurium infection was set up and used to test the therapeutic efficacy of Bac7(1-35). Treatment of infected mice with the peptide injected i.p. immediately after a lethal, intraperithoneal bacterial challenge, increased the mean survival time and reduced significantly the number of viable bacterial cells in liver and spleen of treated mice at 3 days post-inoculum. In 1/3 of the organ homogenates, the bacterial presence was undetectable and this result matches the percentage of cured animals (35%). In an attempt to improve its pharmacokinetic profile, the peptide was conjugated with polyethylene glycol (PEG), a non-toxic, non-immunogenic and FDA-approved polymer. Different strategies of pegylation have been considered to find the best method in terms of chemical yield and of maintenance of biological activity. Pegylation via a thioether ligation resulted the best strategy to obtain a slow active peptide release in human blood components with a reduced renal clearance and an increased bioavailability of Bac7(1-35), as biodistribution analyses demonstrated. Several important pathogens, such as S. enterica, cause disease by surviving and replicating within host cells. Since many AMPs have also immunomodulatory activities, we investigated the effect of Bac7(1-35) on the interaction between macrophages and Salmonella. We carried out phagocytosis assays with macrophages and the results suggest that Bac7(1-35) plays a positive modulatory effect on this function. Phagocytosis assays were also performed to determine if Bac7(1-35) could inhibit survival and replication of intracellular Salmonella. The results show that the peptide inhibits the replication of intracellular Salmonella, suggesting that it can exert its antibacterial activity within eukaryotic cells. Further studies are required to fully understand the details of the Bac7(1-35) biological activities. The results obtained provide encouraging evidence for future investigations on Bac7(1-35) and on the pegylated form Bac7(1-35)CAM-PEG20k also in other models of infection and with different intracellular pathogens.
XXIII Ciclo
1981
Silva, Osmar Nascimento. "Avaliação do potencial terapêutico e estudo da atividade imunomodulatória e antimicrobiana in vitro e in vivo de diferentes formas de clavaninas". Universidade Federal de Juiz de Fora (UFJF), 2010. https://repositorio.ufjf.br/jspui/handle/ufjf/4272.
Texto completoApproved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2017-05-12T15:47:58Z (GMT) No. of bitstreams: 1 osmarnascimentosilva.pdf: 3091891 bytes, checksum: 8e0f2ed0de0225b3ed16c08cdd6fee62 (MD5)
Made available in DSpace on 2017-05-12T15:47:58Z (GMT). No. of bitstreams: 1 osmarnascimentosilva.pdf: 3091891 bytes, checksum: 8e0f2ed0de0225b3ed16c08cdd6fee62 (MD5) Previous issue date: 2010-02-24
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
As infecções relacionadas à assistência à saúde (IrAS), são uma das principais causas de mortalidade e aumento dos custos hospitalares em países desenvolvidos e em desenvolvimento. Nos casos em que um paciente adquire uma IrA e esta não é tratada adequadamente, a mesma pode evoluir para um quadro mais grave, podendo levar a sepse e consequentemente na maioria dos casos a morte. A sepse representa um importante problema de saúde pública, entretanto, um tratamento eficaz para esta síndrome ainda não foi encontrado. Peptídeos antimicrobianos foram relatados para modular a resposta à infecção bacteriana na sepse, independente dos mecanismos de resistência conhecidos para os antibióticos. Desta forma, procurou-se investigar a atividade imunomodulatória de duas formas de clavaninas sobre monócitos RAW 264.7, bem como a atividade antimicrobiana e a citotoxicidade in vitro. Em ensaios in vivo a genotoxicidade, a ação das clavaninas sobre a migração de neutrófilos e a eficácia do tratamento com as clavaninas em um modelo de infecção de ferida operatória por S. aureus e sepse polimicrobiana grave também foram avaliadas. Os estudos in vitro demostraram que as clavaninas inibiram completamente o crescimento de E. coli, K. pneumoniae e S. aureus, preveniram a secreção de citocinas pró-inflamatórias (TNF-α, IL-12) e NO, e aumentaram a secreção de IL-10. Além disso, as clavaninas não apresentaram atividade citotóxica sobre as células RAW 264.7. Nos experimentos in vivo, as clavaninas não apresentaram genotoxicidade, além de apresentarem-se quimoatraentes para neutrófilos. As clavaninas, também, reduziram significativamente as unidades formadoras de colônias de S. aureus no modelo experimental de ferida operatória, e reduziram a mortalidade dos animais sépticos em mais de 50%, quando comparados com animais controle. Devido à sua ação direta sobre células do sistema imune e microorganismos, as clavaninas aparentam ser compostos potenciais para o tratamento de infecções bacterianas graves como a sepse, demonstrando alto valor biotecnológico.
Healthcare-associated infections (HAIs) are a major cause of mortality, also increasing hospital costs in developed and developing countries. When a patient acquires HAIs and this is not properly handled, disease may clearly worst, leading to sepsis and consequently in major to death. Despite of sepsis represents an important public health problem, any effective treatment for this syndrome was obtained until now. In this view, antimicrobial peptides have been reported as modulators of immune response to bacterial infection in sepsis, with independent activity of mechanisms that lead to antibiotic. Thus, the immunomodulatory activity of two different forms of clavanins over RAW 264.7 monocytes, as well the in vitro antimicrobial and cytotoxic activities were here investigated. Furthermore, in vivo genotoxicity assays, the evaluation of clavanins activity on neutrophil migration and also the efficacy of treatment with clavanins in a wound S. aureus infection model and severe polymicrobial sepsis were also evaluated. Moreover, in vitro studies demonstrated that clavanins are able of inhibit the growth of E. coli, K. pneumoniae and S. aureus. Clavanins also prevented the secretion of proinflammatory cytokines (TNF-α, IL-12) and NO, and increased the IL-10secretion. In addition, clavanins showed none cytotoxicity on RAW 264.7 cells. During in vivo experiments, the clavanins showed no genotoxicity, showing however, a clear chemotactic effect for neutrophils. Clavanins also significantly reduced the colony-forming units of S. aureus in an experimental model of surgical wound infection and reduced the mortality of septic animals in more than 50 %, when compared to control group. Due to their direct activities over immune cells and microorganisms, clavanins are potential compounds for the treatment of serious bacterial infections such as sepsis, showing an enormous and remarkable biotechnological value.
Bürkle, Carl-Philipp Stavros. "Die Expression antimikrobieller Peptide (Psoriasin, HBD-2 und HBD-3) in menschlicher Haut und deren Modulation in vivo - eine Untersuchung im xenogenen Haut-Transplantationsmodell". Doctoral thesis, Universitätsbibliothek Leipzig, 2011. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-73827.
Texto completoBorrelli, Alexander P. "Synthetic Genes for Antimicrobial Peptides". Digital WPI, 2003. https://digitalcommons.wpi.edu/etd-theses/427.
Texto completoBorelli, Alexander P. "Synthetic genes for antimicrobial peptides". Link to electronic thesis, 2003. http://www.wpi.edu/Pubs/ETD/Available/etd-0428103-102059/.
Texto completoVaucher, Rodrigo de Almeida. "Influência do peptídeo P34 na expressão gênica em Listeria spp. e estudo da citotoxicidade dos peptídeos P34 e P40". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2010. http://hdl.handle.net/10183/23977.
Texto completoIn this study initial experiments were performed to evaluate synergistic action of the antimicrobial peptide P34 and culture supernatants of some selected lactic acid bacteria isolated from Minas Frescal cheese. The influence of this peptide in the expression of genes in L. monocytogenes and L. seeligeri, their cytotoxicity in differents eukaryotic cells and “in vivo” toxicity was investigated. Also, some tests were carried out o evaluate the cytotoxicity of the antimicrobial peptide P40. The peptide P34 caused a decrease of up to 3 log cycles in viable counts of L. monocytogenes artificially inoculated in cheese. A significant increase in expression of genes dltA, Imo1695 mptA of L. monocytogenes was observed after 96 h incubation of the peptide P34 in cheese. The influence of peptide P34 on the expression of genes associated to components of cell envelope of L. monocytogenes and L. seeligeri, promoted a non significant increase in the levels of transcription of genes dltA, Imo1695 and mptA were observed after incubation of L. monocytogenes for 24 hs at 37°C and 240 hs at 4°C in plates. In L. seeligeri a significant decrease was observed in gene expression dltA. The gene Imo1695 showed a significant decrease in its expression (2000-fold) after inoculation with the peptide P34. A significant decrease of expression was also observed for the gene mptA (31872 - times) after inoculation with the peptide P34 and incubation for 24 hours at 37°C. The inoculation of the plate with the P34 peptide and incubated for 240 hrs at 4°C, showed a non-significant decrease of gene expression. The cytotoxicity of the peptide P34 and P40 was assessed in VERO cells treated with different concentrations (0.02 - 2.5 μg ml- 1). In MTT, NRU and LDH assays the EC50 to the peptide P34 were 0.60, 1.25, 0.65 μg ml-1 and the peptide P40 were 0.30, 0.51 and 0.57 μg ml-1, respectively. The hemolytical activity on human erythrocytes was of (5.8%) and (19%), respectively. The effects on viability, motility and acrosomal exocytosis of humam sperm were also evaluated for peptideP34. There were no hypersensitivity reactions or significant increase in antibody titer during the immunogenicity experiment or death of animals during the acute or subchronic toxicity tests. The LD50 was more the 332.3 ± 0.76 mg/kg. No significant changes in the serum biochemical parameters were observed in the animals treated with the peptide P34. Signs of possible toxicity were no detected in animals in the group treated with 0.825 mg/kg day of peptide P34. In this group only histological changes in the spleen with the presence of megakaryocytes were observed. From these results show the potential o peptide P34 to be used in future as biopreservative in foods.
Vargues, Thomas. "Antimicrobial peptides : structure, function and resistance". Thesis, University of Edinburgh, 2009. http://hdl.handle.net/1842/4076.
Texto completoZhao, Hongxia. "Mode of action of antimicrobial peptides". Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/biola/vk/zhao/.
Texto completoParisi, Rosaura. "Computational design of new antimicrobial peptides". Doctoral thesis, Universita degli studi di Salerno, 2018. http://hdl.handle.net/10556/3018.
Texto completoAntimicrobial peptides (AMP) are evolutionarily conserved components of the innate immune system. They have a broad spectrum of action against bacteria, fungi and viruses. Therefore, AMP are studied as probable substitutes of the traditional antibiotics, for which most pathogens have developed resistance. The main objective of this work was the design of novel linear peptides capable to interact with the cellular membrane of the common pathogens. In this work, sequences of active AMP were carefully obtained from the scientific literature and collected in Yadamp (http://yadamp.unisa.it/), a database of AMP created recently in the laboratory where this project was carried out. In Yadamp, there are information about peptides name, amino acid sequence, length, presence of disulfide bridges, date of discovery, activity and taxonomy. The most relevant chemical-physical properties are also listed. This database is mainly focused on the peptides activities. Experimental MIC values (the lowest concentration of an antimicrobial that inhibits the visible growth of a microorganism) are constantly obtained from careful reading the original papers. In this work, a great contribution was made in the enrichment of the database. In fact, 1009 sequences were added to Yadamp. It currently contains 3142 AMP sequences. For these AMP, 573 molecular descriptors were calculated. In addition, this project also involved the search for new molecular descriptors. Yadamp is a resource for QSAR investigations on AMP. It allows to create subsets of AMP, homogeneous in one, two or more parameters...[abstract by Author]
XXX ciclo
Libros sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Hansen, Paul R., ed. Antimicrobial Peptides. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6737-7.
Texto completoMatsuzaki, Katsumi, ed. Antimicrobial Peptides. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3588-4.
Texto completoPhoenix, David A., Sarah R. Dennison y Frederick Harris. Antimicrobial Peptides. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2013. http://dx.doi.org/10.1002/9783527652853.
Texto completoGiuliani, Andrea y Andrea C. Rinaldi, eds. Antimicrobial Peptides. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-594-1.
Texto completoHarder, Jürgen y Jens-M. Schröder, eds. Antimicrobial Peptides. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-24199-9.
Texto completoJoan, Marsh, Goode Jamie, Ciba Foundation y Symposium on Antimicrobial Peptides (1994 : Ciba Foundation)d), eds. Antimicrobial peptides. Chichester, Eng: Wiley, 1994.
Buscar texto completoDrider, Djamel y Sylvie Rebuffat, eds. Prokaryotic Antimicrobial Peptides. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-7692-5.
Texto completoHiemstra, Pieter S. y Sebastian A. J. Zaat, eds. Antimicrobial Peptides and Innate Immunity. Basel: Springer Basel, 2013. http://dx.doi.org/10.1007/978-3-0348-0541-4.
Texto completoShafer, William M., ed. Antimicrobial Peptides and Human Disease. Berlin, Heidelberg: Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-29916-5.
Texto completoAntimicrobial peptides: Methods and protocols. New York: Humana Press/Springer, 2010.
Buscar texto completoCapítulos de libros sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Afacan, Nicole J., Laure M. Janot y Robert E. W. Hancock. "Host Defense Peptides: Immune Modulation and Antimicrobial Activity In Vivo". En Antimicrobial Peptides and Innate Immunity, 321–58. Basel: Springer Basel, 2012. http://dx.doi.org/10.1007/978-3-0348-0541-4_13.
Texto completoKolar, Satya Sree, Hasna Baidouri, Maria Luisa Mangoni y Alison M. McDermott. "Methods for In Vivo/Ex Vivo Analysis of Antimicrobial Peptides in Bacterial Keratitis: siRNA Knockdown, Colony Counts, Myeloperoxidase, Immunostaining, and RT-PCR Assays". En Methods in Molecular Biology, 411–25. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6737-7_30.
Texto completoPark, Andrew J., Jean-Phillip Okhovat y Jenny Kim. "Antimicrobial Peptides". En Clinical and Basic Immunodermatology, 81–95. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-29785-9_6.
Texto completoChakraborti, Srinjoy y Sanjay Ram. "Antimicrobial Peptides". En Management of Infections in the Immunocompromised Host, 95–113. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-77674-3_5.
Texto completoMarcos, Jose F. y Paloma Manzanares. "Antimicrobial Peptides". En Antimicrobial Polymers, 195–225. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118150887.ch8.
Texto completoJack, Ralph W., Gabriele Bierbaum y Hans-Georg Sahl. "Antimicrobial Peptides". En Lantibiotics and Related Peptides, 1–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-662-08239-3_1.
Texto completoLata, Sneh y Gajendra Raghava. "Antimicrobial Peptides". En Encyclopedia of Systems Biology, 31–33. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-9863-7_87.
Texto completoGanz, T. y R. I. Lehrer. "Antimicrobial Peptides". En Handbook of Experimental Pharmacology, 295–304. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-55742-2_16.
Texto completoSørensen, Ole E. "Antimicrobial Peptides in Cutaneous Wound Healing". En Antimicrobial Peptides, 1–15. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-24199-9_1.
Texto completoZasloff, Michael. "Antimicrobial Peptides: Do They Have a Future as Therapeutics?" En Antimicrobial Peptides, 147–54. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-24199-9_10.
Texto completoActas de conferencias sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Kašperová, Alena, Jaroslav Turánek, Václav Čeřovský y Milan Raška. "In vitro and in vivo antimicrobial effect of lasioglossins on the Candida albicans". En XIIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2011. http://dx.doi.org/10.1135/css201113054.
Texto completoTůmová, Tereza, Petra Lovecká, Václav Čeřovský y Jiřina Slaninová. "Real time in vivo monitoring of cytotoxic activity of two different antimicrobial peptides lasioglossin III and lasiocepsin". En XIIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2011. http://dx.doi.org/10.1135/css201113151.
Texto completoLammi, Carmen. "From the bench to the bedside: the history of lupin bioactive peptides as useful ingredient for the prevention of metabolic syndrome". En 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/bwgm4089.
Texto completoKrasnodembskaya, Anna, Yuanlin Song, Jae-Woo Lee y Michael A. Matthay. "Human Mesenchymal Stem Cells Exert Antimicrobial Activity In Vitro And In Vivo In Part Through The Secretion Of The Antimicrobial Peptide LL-37". En American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1246.
Texto completoTuránek, Jaroslav, Michaela Škrabalová y Pavlína Knötigová. "Antimicrobial and anticancer peptides". En XIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2009. http://dx.doi.org/10.1135/css200911128.
Texto completoKaygorodova, I. A. "ANTIMICROBIAL PEPTIDES OF PARASITIC LEECHES". En ECOLOGICAL PROBLEMS OF LAKE BAIKAL BASIN. Buryat Scientific Center of SB RAS Press, 2022. http://dx.doi.org/10.31554/978-5-7925-0621-3-2022-59-61.
Texto completoČeřovský, Václav, Rudolf Ježek, Vladimír Fučík y Jiřina Slaninová. "Antimicrobial peptides from the venom of Vespidae". En Xth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2007. http://dx.doi.org/10.1135/css200709025.
Texto completoDoležílková, Ivana, Martina Macková y Tomáš Macek. "Short peptides with antimicrobial activity from plants". En XIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2009. http://dx.doi.org/10.1135/css200911025.
Texto completoEhala, Sille, Petr Niederhafner, Václav Čeřovský, Pavel Řezanka, David Sýkora, Vladimír Král y Václav Kašička. "Analysis of antimicrobial peptides by capillary electrophoresis". En XIIth Conference Biologically Active Peptides. Prague: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2011. http://dx.doi.org/10.1135/css201113037.
Texto completoBo, Shi-ru, Jiang-hua Yu, Ya-li Wang y Quan-kai Wang. "Preparation and Antimicrobial Activity of Antimicrobial Peptides from Plum Deer Antler". En 2017 5th International Conference on Mechatronics, Materials, Chemistry and Computer Engineering (ICMMCCE 2017). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/icmmcce-17.2017.142.
Texto completoInformes sobre el tema "Antimicrobial PEPTIDES IN VIVO"
Doherty, Laurel A., Morris Slutsky y Jason W. Soares. Antimicrobial Peptides with Differential Bacterial Binding Characteristics. Fort Belvoir, VA: Defense Technical Information Center, marzo de 2013. http://dx.doi.org/10.21236/ada577726.
Texto completoMierswa, S. C., T. H. Lee y M. C. Yung. Developing an engineered therapeutic microbe to release antimicrobial peptides (AMPs). Office of Scientific and Technical Information (OSTI), agosto de 2019. http://dx.doi.org/10.2172/1558856.
Texto completoYung, M. C. Engineering a therapeutic microbe for site-of-infection delivery of encapsulated antimicrobial peptides (AMPs). Office of Scientific and Technical Information (OSTI), octubre de 2019. http://dx.doi.org/10.2172/1573149.
Texto completoVouros, Paul y Terrance Black. Solid Phase Peptide Synthesis of Antimicrobial Peptides for cell Binding Studies: Characterization Using Mass Spectrometry. Fort Belvoir, VA: Defense Technical Information Center, noviembre de 2002. http://dx.doi.org/10.21236/ada412571.
Texto completoNoga, Edward J., Angelo Colorni, Michael G. Levy y Ramy Avtalion. Importance of Endobiotics in Defense against Protozoan Ectoparasites of Fish. United States Department of Agriculture, septiembre de 2003. http://dx.doi.org/10.32747/2003.7586463.bard.
Texto completoAltstein, Miriam y Ronald Nachman. Rationally designed insect neuropeptide agonists and antagonists: application for the characterization of the pyrokinin/Pban mechanisms of action in insects. United States Department of Agriculture, octubre de 2006. http://dx.doi.org/10.32747/2006.7587235.bard.
Texto completoDroby, Samir, Michael Wisniewski, Martin Goldway, Wojciech Janisiewicz y Charles Wilson. Enhancement of Postharvest Biocontrol Activity of the Yeast Candida oleophila by Overexpression of Lytic Enzymes. United States Department of Agriculture, noviembre de 2003. http://dx.doi.org/10.32747/2003.7586481.bard.
Texto completoAltstein, Miriam y Ronald J. Nachman. Rational Design of Insect Control Agent Prototypes Based on Pyrokinin/PBAN Neuropeptide Antagonists. United States Department of Agriculture, agosto de 2013. http://dx.doi.org/10.32747/2013.7593398.bard.
Texto completo